Validity Report
Basic Report
US8895557B2 — Pharmaceutical formulations of ecteinascidin compounds
Priority Date: 2004-10-29, Publication Date: 2014-11-25, Current Assignee: Pharmamar SAReport Generated: 2020-07-31
Preview Results|Predictive Analytics|Preview CPC Technology Profile

Preview Results

Patent Id
Score
Title
Patent Type
Publication Date
Priority Date
Search Efficiency
Original Assignee
Current Assignee
EP1365808A2●●●●●COMPOSITIONS FOR ANTITUMOUR TREATMENT CONTAINING ECTEINASCIDIN 743GRANT2003-12-032000-11-06GreatPharmamar SAPharmamar SA
US4675311A●●●●●Pharmaceutical compositions containing anthracycline glycosidesGRANT1987-06-231984-10-22GreatFarmitalia Carlo Erba SpAPfizer Italia SRL
US6586574B1●●●●●Stabilization of freeze-dried cakeGRANT2003-07-011999-08-17GreatNovo Nordisk ASNovo Nordisk Health Care AG
US5650390A●●●●●Gonadotropin containing pharmaceutical compositions with sucrose stabilizerGRANT1997-07-221991-12-18GreatApplied Research Systems ARS Holding NVMerck Serono SA, Applied Research Systems ARS Holding NV
EP1691809A1●●●●●COMBINATION THERAPY COMPRISING THE USE OF ET-743 AND PACLITAXEL FOR TREATING CANCERGRANT2006-08-232003-11-14GreatPharmamar SAPharmamar SA
EP1675592A1●●●●●IMPROVED ANTITUMORAL COMBINATIONS CONTAINING ET-743 AND A CRUCIFEROUS INDOLE COMPOUNDGRANT2006-07-052003-10-15GreatPharmamar SAPharmamar SA
EP1827500A2●●●●●PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINESCIDIN 743GRANT2007-09-052004-10-26GreatPharmamar SA, Ortho Biotech Products LPPharmamar SA, Ortho Biotech Products LP
US6683100B2●●●●●Organic compoundsGRANT2004-01-271999-01-19GreatNovartis AGNovartis AG
US20050220758A1●●●●●Lyophilised preparation comprising immunocytokinesAPPLICATION2005-10-062002-02-06GreatMerck Patent GmbHMerck Patent GmbH
US20030203876A1●●●●●Organic compoundsAPPLICATION2003-10-301998-02-05Great
EP1689402A1●●●●●COMBINATION THERAPY COMPRISING THE USE OF ET-743 AND DOXORUBICIN FOR TREATING CANCERGRANT2006-08-162003-11-14GreatPharmamar SAPharmamar SA
EP1503797B1●●●●●INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHRACENEDIONE DERIVATIVE WITH ANTI-TUMORAL ACTIVITYGRANT2007-12-262002-05-16GreatCell Therapeutics Europe SRLCell Therapeutics Europe SRL
EP1791528A1●●●●●LYOPHILISATE CONTAINING N-DIAMINOMETHYLENE-2-METHYL-4 5-DI-(METHYLSULFONYL)-BENZAMIDEGRANT2007-06-062004-09-22GreatMerck Patent GmbHMerck Patent GmbH
EP1689404A1●●●●●COMBINATIONGRANT2006-08-162003-11-13GreatPharmamar SAPharmamar SA
EP1210361B1●●●●●STABILISATION OF FREEZE-DRIED CAKEGRANT2004-04-141999-08-17GreatNovo Nordisk Health Care AGNovo Nordisk Health Care AG
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●Great●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●Great●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●Great●●●●●●●●●●
Keep up the Momentum with full ranked/tiered results. One-time price.

Predictive Analytics

Composite Research Score (1-10)
5
  MODERATE
Art VolumeMEDIUM
Tech ComplexityORDINARY
Priority DateMID
Tech DiversityNARROW
Expert Services Estimate$2,550 — $3,000
There is where a graph would go if the browser supported it.
There is where a graph would go if the browser supported it.

Preview CPC Technology Profile

Possible Classes
697
Recommended Classes
175
Government Assigned Classes
11
CPC
Title
Score
A61K47/26Carbohydrates  e.g. sugar alcohols  amino sugars  nucleic acids  mono-  di- or oligo-saccharides| Derivatives thereof  e.g. polysorbates  sorbitan fatty acid esters or glycyrrhizin●●●●●
A61K31/4995Pyrazines or piperazines forming part of bridged ring systems●●●●●
A61K9/0019Injectable compositions| Intramuscular  intravenous  arterial  subcutaneous administration| Compositions to be administered through the skin in an invasive manner | non-active ingredients are additionally classified in | (ref: A61K47/00)●●●●●
A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems  e.g. quinoxaline  phenazine●●●●●
A61K31/704attached to a condensed carbocyclic ring system  e.g. sennosides  thiocolchicosides  escin  daunorubicin | digitoxin | (ref: A61K31/7048)●●●●●
A61K31/337having four-membered rings  e.g. taxol●●●●●
A61K47/50the non-active ingredient being chemically bound to the active ingredient  e.g. polymer-drug conjugates●●●●●
A61K47/183Amino acids  e.g. glycine  EDTA or aspartame●●●●●
A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds  e.g. carbomers |   poly(meth)acrylates  or polyvinyl pyrrolidone●●●●●
A61K47/02Inorganic compounds●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
Keep up the Momentum with full ranked/tiered results. One-time price.
Terms of Service | Privacy Policy | Contact | COPYRIGHT 2020. TECHSON IP, LLC. LIMESTONE, TECHSON, AND INTELLIGENT PROPERTY ARE REGISTERED TRADEMARKS. TECHSON IP IS NOT A LAW FIRM AND DOES NOT PROVIDE LEGAL OPINIONS OR LEGAL ADVICE.